Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproductive treatment

Cochrane Database of Systematic Reviews

Volumn , Issue 3, 2009, Pages

  Maheshwari, Abha ^a   Bhattacharya, Siladitya ^b   Daya, Salim ^c   Gibreel, Ahmed Fathy ^a   Siristatidis, Charalambos S ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b ABERDEEN MATERNITY HOSPITAL   (United Kingdom)

^c University of Aberdeen ^*  (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GONADORELIN AGONIST;

CLINICAL TRIAL; DOWN REGULATION; DRUG EFFECT; FERTILIZATION IN VITRO; HUMAN; HYPOPHYSIS FUNCTION; INFERTILITY; INFERTILITY THERAPY; INTRACYTOPLASMIC SPERM INJECTION; REVIEW; TREATMENT OUTCOME;

EID: 70049093327     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006919.pub2     Document Type: Review

References (13)

1. Belchetz PE, Plant TM, Nakai Y, Keogh EJ, Knobil E. Hypophyseal responses to continuous and intermittent delivery of hypothalamic gonadotropin-releasing hormone. Science 1978;202:631-633 (Pubitemid 9055618)
2. Deeks JJ, Higgins JPT, Altman DG, editors. Analysing and presenting results. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. John Wiley & Sons, Ltd: Chichester, UK.
3. Donderwinkel PF, Schoot DC, Pache TD, de Jong FH, Hop WC, Fauser BC. Luteal function following ovulation induction in polycystic ovary syndrome patients using exogeneous gonadotrophins in combination with a gonadotrophn-releasing hormone agonist. Human Reproduction 1993;8:2027-2032
4. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Library Issue 4 Sept 2008. Chichester UK: John Wiley and Sons Ltd, 2008, 5.0.0 (updated February 2008).
5. Homburg R, Arman NA, Eshel A, Adams J, Jacobs HS. Influence of serumluteinizing hormone concentrations on ovulation, conception, and early pregnancy loss in polycystic ovary syndrome. BMJ 1988;297:1024-1026 (Pubitemid 18247571)
6. Howles C, Macnamee MC, Edwards RG. Follicular development and early luteal function of conception and non-conceptional cycles after human in vitro fertilization: endocrine correlates. Human Reproduction 1987;2:17-21. (Pubitemid 17032181)
7. Hughes EG, Fedorkow DM, Daya S, Sagle MA, Van de Koppel P, Collins JA. The routine use of gonadotropin-releasing hormone agonists prior to in vitro fertilization and gamete intrafallopian transfer: a meta-analysis of randomized trials. Fertility and Sterility 1992;58:888-896
8. Knobil E. The neuroendocrine control of the menstrual cycle. Recent Progress in Hormone Research 1980;36:53-81.
9. Regan L, Owen EJ, Jacobs HS. Hypersecretion of luteinizing hormone, infertility and miscarriage. Lancet 1990;336:1141-1144 (Pubitemid 20362903)
10. Smitz J, Erard P, Camus M, Devroey P, Tournaye H, Wisanto A, et al. Pituitary gonadotrophin secretory capacity during the luteal phase in superovulation using GnRH-agonists and HMG in a desensitization or flare-up protocol. Human Reproduction 1992;7:1225-1229
11. Stanger J, Yovich JJ. Reduced in vitro fertilization of human oocytes from patients with raised basal luteinizing hormone levels during the follicular phase. British Journal of Obstetrics and Gynaecology 1985;92:385-393 (Pubitemid 15114221)
12. Stuck AE, Rubenstein LZ, Wieland D. Bias inmeta-analysis detected by a simple, graphical test. Asymmetry detected in funnel plot was probably due to true heterogeneity. BMJ 1998;316(7129):469-470
13. Westergaard LG, Laursen SB, Anderson CY. Increased risk of early pregnancy loss by profound suppression of luteinizing hormone during ovarian stimulation in normogonadotrophic women undergoing assisted reproduction. Human Reproduction 2000;15:1003-1008